GalNAc-T2 CRISPR/Cas9 KO Plasmid (m): sc-430824
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GalNAc-T2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GalNAc-T2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GalNAc-T2 CRISPR/Cas9 KO Plasmid (m) | sc-430824 | 20 µg | $397.00 |
Overview
Galnt2 encodes the mouse polypeptide N-acetylgalactosaminyltransferase GalNAc-T2, a Golgi-resident enzyme that initiates mucin-type O-linked glycosylation by transferring GalNAc to serine/threonine residues on secreted and membrane proteins. By shaping O-glycan composition and density, GalNAc-T2 influences protein folding, protease susceptibility, receptor–ligand interactions, and extracellular matrix organization. This glycosylation program interfaces with secretory pathway quality control and can modulate signaling and cell–cell communication through altered glycoprotein trafficking and surface presentation. Dysregulated O-glycosylation is widely implicated in inflammation, metabolic phenotypes, and tumor-associated glycan remodeling, making Galnt2 a useful node for studying glycoproteome changes relevant to disease mechanisms.
GalNAc-T2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Galnt2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Galnt2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Galnt2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GalNAc-T2 protein expression.
This CRISPR knockout system enables efficient generation of Galnt2-deficient cell models for investigation of GalNAc-T2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Galnt2 exon(s) critical for GalNAc-T2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Galnt2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GalNAc-T2 CRISPR/Cas9 KO Plasmid (m) and GalNAc-T2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Galnt2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GalNAc-T2 HDR Plasmid (m) and GalNAc-T2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Galnt2 homology arms to support homology-directed repair at defined Galnt2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.